These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34154827)

  • 1. Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
    Fernández-Rodríguez B; Dupouy J; Harroch E; Fabre-Delcros MH; Barthélémy C; Loubière P; Barange K; Brefel-Courbon C; Rascol O; Ory-Magne F
    Rev Neurol (Paris); 2021 Oct; 177(8):919-923. PubMed ID: 34154827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced therapies in Parkinson's disease: Long-term retrospective study.
    Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
    Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. l-Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior.
    Valldeoriola F; Santacruz P; Ríos J; Compta Y; Rumià J; Muñoz JE; Martí MJ; Tolosa E
    Brain Behav; 2017 Nov; 7(11):e00848. PubMed ID: 29201549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
    Elkouzi A; Ramirez-Zamora A; Zeilman P; Barabas M; Eisinger RS; Malaty IA; Okun MS; Almeida L
    Ann Clin Transl Neurol; 2019 Oct; 6(10):1989-1995. PubMed ID: 31518070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Liu XD; Bao Y; Liu GJ
    Front Neurol; 2019; 10():934. PubMed ID: 31507529
    [No Abstract]   [Full Text] [Related]  

  • 7. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
    Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
    Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
    Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient preference of device-based treatment of Parkinson's disease.
    Aydemir ST; Kumcu MK; Ulukan Ç; Bakirarar B; Akbostancı MC
    Int J Neurosci; 2022 Sep; 132(9):925-929. PubMed ID: 33208012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
    Moes HR; Groenendal-Laurensse JWMJ; Drent M; Tissingh G; van Laar T
    J Parkinsons Dis; 2020; 10(3):935-944. PubMed ID: 32675420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.